Pain and end-stage renal disease are associated with reduced survival and poor quality of life in sickle cell disease (SCD). 1 -4 Morphine and its congeners are used to treat severe pain after vasoocclusive crises and ongoing chronic pain in SCD. 5 6 As a possible complication of this therapeutic approach, we observed previously that clinically relevant doses of morphine incite kidney pathology, glomerular enlargement, and albuminuria in wild-type and transgenic sickle mice. 7 -9 Here, we investigate the mechanism(s) by which morphine stimulates renal disease.
In addition to their induction of analgesia, opioids activate growth, survival, and cytoprotection via opioid receptors (OPs) on multiple cell types including glomerular mesangial cells. 7 10-15 Mitogenic signalling induced by morphine involves co-activation of receptor tyrosine kinases (RTKs) for vascular endothelial growth factor receptor-2 and plateletderived growth factor receptor-b (PDGFR-b) and downstream mitogenic signalling of mitogen-activated protein kinase/ extracellular signal regulated kinase (MAPK/ERK) and signal transducer and activator of transcription 3 (Stat3) pathways via m-opioid receptor (MOP) on endothelium and pericytes. 16 -19 PDGFR-b signalling is critical to mesangial function, because overexpression or deletion of PDGF-B or PDGFR-b influences mesangial proliferation and glomerular pathology in the kidney. 20 We investigated the mitogenic signalling of morphine in vitro in the mesangial cells and in vivo in the kidneys of transgenic mice expressing sickle haemoglobin (HbS) or normal human haemoglobin (HbA). Furthermore, we examined whether treatment with morphine influenced renal function in HbS mice.
Methods
All mouse studies were performed after receiving approval from our Institutional Animal Care and Use Committee (#0806A37663).
Mice
Homozygous (BERK), hemizygous (hBERK1), and control (HbA-BERK) transgenic mice were used. BERK, the homozygous sickle mice, have knockout of both murine a-and b-globins and carry the linked transgenes for human a-and b S -globins and express .99% human HbS. 21 BERK mice present the sickle phenotype of human disease including renal disease, haemolysis, reticulocytosis, anaemia, organ damage, pain, and reduced survival. 21 -23 hBERK1 mice are hemizygous for knockout of murine b-globin, but are homozygous for knockout of murine a-globin and carry a single copy of the linked transgenes for human a-and b S -globins. They express 25% human HbS and show kidney pathology. 9 21 22 HbA-BERK (control) mice exclusively express human a-and b A -globins (thus, normal human HbA) but no murine a-or b-globins. 21 All three types of mice are littermates and hence have similar genetic background. Mice were bred ,12 h light-to-dark cycle, in our pathogen-free facility and phenotyped by isoelectric focusing for Hb and by real-time polymerase chain reaction for transgene number.
Cell culture
Mouse mesangial cells (American Type Culture Collection, Manassas, VA, USA) were cultured using a 3:1 mixture of Dulbecco's modification of Eagle's medium and F12-Hams medium, respectively, supplemented with 10% heat-inactivated fetal calf serum, 100 U ml 21 penicillin, 100 U ml 21 streptomycin, and 10 mM HEPES (all from Invitrogen, Carlsbad, CA, USA). Cells were stimulated with 1 mM morphine or 20 ng ml 21 PDGF-BB (Invitrogen) in the presence or absence of the PDGFR tyrosine kinase inhibitor, AG-1296 (10 mM; Cayman Chemicals, Ann Arbor, MI, USA), naloxone (1 mM), methylnaltrexone (MNTX) 0.1 mM (Wyeth Pharmaceuticals, Philadelphia, PA, USA) and norbinaltorphimine (nor-BNI) 1 mM (Sigma-Aldrich, St Louis, MO, USA).
Drugs and treatments
Six each of HbA-BERK and hBERK1 and 12 BERK mice were divided into two equal groups and s.c. injected with either phosphate-buffered saline (PBS) or morphine sulphate (Baxter Esilerderle Healthcare, Cherry Hill, NJ, USA) daily (0.75, 1.4, 2.14, 2.8, 3.6, and 4.3 mg kg 21 divided doses in Weeks 1-6, respectively; equivalent to 50-301 mg in a 70 kg human per day). At the end-point, mice were killed with compressed carbon dioxide and the kidneys were removed immediately for analysis.
MOP-1 and KOP-1 gene silencing
A cocktail of sequences of siRNA specifically targeting the mouse MOP-1 and KOP-1 genes (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were used (for further information see Supplementary material).
Each siRNA consisted of a pool of three-target-specific 20-25 nucleotide siRNAs. On Day 1, mouse mesangial cells were plated in a six-well plate. On Day 2, 100 nM siRNA and 4 ml of transfection agent si-PORT Lipid (Ambion, Inc., Austin, TX, USA) were separately diluted with OPTI-MEM I medium (Invitrogen) and then mixed rapidly and incubated at room temperature for 15 min to form a complex. The siRNA/ transfection agent complex was overlaid on the mesangial cells drop wise. Control, scramble-siRNA (Santa Cruz Biotechnology, Inc.) was used as a negative control. After fourth incubation, an equal volume of mesangial cell growth medium was added to the cells followed by overnight incubation. Cells were then used to determine gene expression by reverse transcription -polymerase chain reaction (RT -PCR) or were used for other experiments.
Western immunoblotting
Kidney and mesangial cell lysates containing 100 mg of protein were resolved on a 3-15% gradient sodium dodecyl sulphatepolyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Immobilon, Millipore, Bedford, MA, USA) as described previously. 7 For immunoblotting, we used antibodies to phospho-p44/42 MAPK/ERK Thr 202/Tyr 204 (1:500), total p44/42 MAPK/ERK (1:500), phospho-Stat3 Tyr 705 (1:500), phospho-Stat3 Ser 727 (1:500), and total-Stat3 (1:500) from Cell Signalling Technology (Beverly, MA, USA); phospho-PDGFR-b Tyr 716 (1:250) from Upstate (Lake Placid, NY, USA); total PDGFR-b (1:500) from Cell Signalling Technology (Beverly); Thy-1(1:200). Immunoreactive proteins were seen using a species-specific antibody linked to alkaline phosphate followed by development of chemiluminescent signals using the ECF western blotting system (Amersham Life Sciences, Buckinghamshire, UK). Chemiluminescent signals were acquired using a Storm 860 PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA) and densitometric analysis was performed using Image J software (NIH, Bethesda, MD, USA).
Proliferation assay
Proliferation of mesangial cells was measured using bromylated deoxyuridine (BrdU) cell proliferation enzyme-linked immunosorbent assay (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. 7 Briefly, 2000 cells per well were seeded on a 96-well plate in 10% fetal calf serum containing mesangial cell medium. Cells were allowed to adhere to the plate overnight and then incubated overnight with 0.1% fetal calf serum containing medium. Cells were pre-incubated with AG-1296, naloxone, nor-BNI, MNTX, or sunitinib (2 mM, Pfizer, New York, NY, USA) for 60 min; then morphine or PDGF-BB was added for an additional 48 h. Appropriate control wells were used for each experiment.
Reverse transcription -polymerase chain reaction
Total RNA was isolated using Trizol reagent from the kidneys of 5 HbA-BERK, 7 hBERK1, and 6 BERK. Five micrograms of total Morphine-induced PDGFR-b signalling in kidney RNA were reverse transcribed using the first-strand synthesis system (Invitrogen). Taq DNA polymerase (Continental Lab Products, San Diego, CA, USA) was used for performing PCRs. Primer sequences are available in the Supplementary material. Amplification was performed for 30 cycles at 948C for 50 s, 568C for 50 s, and 728C for 50 s with a final extension cycle for 10 min at 728C in a PTC-100 thermocycler (MJ Research, Waltham, MA, USA) as described earlier. 7 DNA samples were seen using ethidium bromide by 2% agarose gel electrophoresis and sequenced (Microchemical Facility, University of Minnesota) to verify that they matched the expected DNA sequences. Densitometric analysis of the bands was performed using Image J (NIH).
Immunofluorescent staining
Fresh kidneys were embedded in optimum cutting temperature compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and flash frozen in isopentane/liquid nitrogen. Cryo-sections were cut at 4 mm. Sections were blocked with 3% donkey serum in PBS for 30 min at 378C and incubated with primary antibodies diluted in 3% donkey serum in PBS for 60 min at room temperature.
Immunostaining was performed as described by us earlier for kidney sections with slight modifications to accommodate different antibodies used for co-staining in addition to those used by us earlier (see Supplementary material). 23 Primary antibodies for MOP and KOP did not show any immunoreactivity on the sections of kidneys from MOP-and KOP-knockout mice, respectively ( Supplementary Fig. S1 ). In parallel, negative controls were incubated with an isotype-matched immunoglobulin G and secondary antibodies.
Immunofluorescent images were acquired using an Olympus 1X70 microscope with a ×1 eyepiece and a ×100 objective fitted with an Olympus DP70 digital camera (Olympus, Tokyo, Japan).
Urine and serum chemistry
Six each (total, 12) of BERK mice were treated with PBS or morphine as described in 'Drugs and Treatments' above. Urine was collected for a 24 h period using metabolic cages. BUN and urine protein and creatinine were estimated using urea and protein assay kits (Bio-assay systems, Hayward, CA, USA) and a creatinine assay kit (Cayman Chemicals). BUN clearance (C) was calculated using the equation, C¼(U×V )/P, where U and P are urinary and BUN concentration, and V is urine flow rate in ml min 21 . Urine volume and BUN were analysed in six PBS-and six morphine-treated mice, whereas urine protein and BUN clearance were analysed in six PBSand three morphine-treated mice.
Data and statistical analysis
Data are expressed as the mean (SD). Comparisons were made using Mann -Whitney U-test when n¼3 and using analysis of variance with Bonferroni's post hoc test when n≥5. Statistical significance was defined as P,0.05.
Results

Morphine stimulates mitogenic signalling by co-activating PDGFR-b via OPs in kidney mesangial cells
Mesangial cells stimulated with morphine in vitro showed a time-dependent increase in the phosphorylation of PDGFR-b and MAPK/ERK (Fig. 1A) . Morphine-induced phosphorylation of MAPK/ERK was abrogated by naloxone and by AG1296, a pharmacological inhibitor of PDGFR, suggesting that morphine stimulates mitogenic signalling via OPs and PDGFR-b (Fig. 1B) . PDGF-BB also stimulated MAPK/ERK phosphorylation, which was inhibited by AG1296 or naloxone, indicative of a cross-talk between PDGFR-b and OPs. Silencing of MOP and KOP on mesangial cells inhibited morphine-induced phosphorylation of MAPK/ERK, suggesting that morphine stimulates MAPK/ ERK signalling via MOP and KOP (Fig. 1C) . Interestingly, silencing of MOP and KOP also inhibited PDGF-BB-induced MAPK/ERK phosphorylation, indicating that OPs may contribute to PDGFR-b signalling (Fig. 1D ). MAPK/ERK phosphorylation by morphine or PDGF-BB was inhibited by OP antagonists, MNTX and nor-BNI ( Fig. 1E and F ). These data show that morphine acts via OPs to stimulate mitogenic signalling by co-activating PDGFR-b.
Morphine-induced mesangial cell proliferation depends upon OPs, and PDGFR-b
Morphine-induced proliferation was prevented by PDGFR inhibition using AG1296 or sunitinib (Sutent), a clinically used inhibitor of PDGFR and other growth factor receptors ( Fig. 2) . Similarly, morphine-induced proliferation was abrogated by OP antagonism using naloxone, MNTX, or nor-BNI. Sutent and nor-BNI also inhibited the basal proliferation of mesangial cells, while naloxone and MNTX did not have a significant effect when compared with PBS.
MOP and KOP expression is increased in the sickle kidney
Kidneys of all three types of mice showed the expression of MOP and KOP, but not that of DOP (Fig. 3A and B ). However, the expression of both MOP and KOP was significantly higher in BERK kidneys when compared with HbA-BERK. MOP and KOP expression was increased throughout the kidney in the BERK sickle mouse kidney including the glomerular epithelium and mesangium (Fig. 3C) . In HbA-BERK, MOP was weakly expressed throughout the kidney, whereas KOP appeared to be strongly expressed on the vasculature when compared with other cells of the HbA-BERK kidney. More than one band for MOP was seen in HbA-BERK kidney when compared with a single band in sickle kidneys (Fig. 3A ).
Morphine treatment of mice promotes mitogenic signalling in the kidney
Treatment of HbA-BERK, hBERK1, and BERK mice for 6 weeks with morphine resulted in increased phosphorylation of PDGFR-b, Stat3, and MAPK/ERK, when compared with PBS-treated Morphine-induced PDGFR-b signalling in kidney mice (Fig. 4) . Expression of the mesangial cell-specific protein, Thy1, also increased in morphine-treated kidneys. Kidneys of sickle BERK mice, which have the highest level of HbS expression, showed higher constitutive phosphorylation of PDGFR-b, Stat3, and MAPK/ERK and Thy1 expression when compared with HbA-BERK or hBERK1. Morphine further activated these signalling pathways in BERK.
Morphine treatment influences renal function in sickle mice
Morphine treatment of BERK mice for 6 weeks led to complete inhibition of micturition in three of six mice, while the other three mice showed 60% decreased urinary volume when compared with PBS-treated mice over a 24 h period (Fig. 5A) . BUN levels increased while BUN clearance decreased significantly upon morphine treatment when compared with PBS (P,0.01; Fig. 5B and C). A 2.5-fold increase occurred in urinary protein in morphine when compared with PBS-treated BERK mice (P,0.01, vs PBS) ( Fig. 5D ).
Discussion
We demonstrate that chronic exposure to morphine stimulates mitogenic signalling via co-activation of PDGFR-b in the kidney of control and sickle mice. Notably, morphine also impaired renal function in BERK sickle mice. Morphine stimulates mesangial cell proliferation through OP-mediated mitogenic signalling, which may in part contribute to renal disease. As morphine is often used as an analgesic for chronic pain, its use may exacerbate existing renal disease in SCD. We identify several molecular components critical to morphine's mitogenic activity in the kidney, including OPs and PDGFR-b, which could potentially be targeted with FDA-approved drugs, such as MNTX and PDGFR-b inhibitors, to prevent morphine-induced renal injury without compromising analgesia. Opioids and their receptors expressed in the central nervous system have also been demonstrated in the kidney. 7 24 25 We observed an increase in expression of MOP and KOP in transgenic sickle mouse kidneys when compared with control mice. While it is unclear whether increased MOP and KOP expression is a cause or consequence of renal disease, our OP antagonism and silencing studies clearly show that morphine-induced renal effects are mediated by OPs. Previous studies suggest that morphine contributes to mesangial expansion by increasing glomerular mesangial cell proliferation, matrix synthesis, and immune complex formation. 12 26 In the current study, using both in vitro mesangial cells and in vivo mouse models, we find that morphine stimulates mesangial cell proliferation, via phosphorylation of PDGFR-b and MAPK/ ERK signalling, suggesting that morphine has a mesangial cellspecific effect. Notably, our finding that BERK kidneys express higher levels of MOP and KOP compared with control mouse kidneys is consistent with the higher levels of constitutive phosphorylation of growth signalling pathways and Thy1 protein expression seen in BERK kidneys when compared with HbA-BERK kidneys. Thus, our study provides clear in vivo evidence that morphine promotes mitogenic signalling in the kidney.
PDGFR-b, Stat3, and MAPK/ERK signalling are key regulatory pathways in cellular proliferation and kidney disease. 27 -29 OPs activate MAPK/ERK and Stat3 phosphorylation 7 13 16 30 and co-activate RTKs for growth factors including PDGFR-b. 7 13 16 17 19 27 30 -32 Deletion of PDGF-B or PDGFR-b results in the loss of mesangium in the glomerulus, while systemic overexpression of PDGF-B leads to mesangioproliferative alterations and renal fibrosis. 20 Morphine stimulates PDGF-BB expression in endothelial cells. 19 33 Therefore, it is likely that co-activation of PDGFR-b may amplify its mitogenic signalling in the kidney, which is consistent with our earlier observations on morphine-induced kidney growth, mesangial proliferation, and glomerular volume expansion in wild-type and sickle mice. 7 -9 Glomerulomegaly may be a precursor to glomerular sclerosis and result in increased urinary protein excretion. 34 Morphine-induced mesangial signalling may contribute to impairment in renal function in sickle mice. However, morphine also induces vacuolization of tubular epithelium and tubular damage in mice and rats. 9 It is likely that morphine-induced tubular pathology in part contributes to proteinuria observed in BERK mice treated with morphine for 6 weeks. Our observations are consistent with the significantly increased BUN in Wistar rats treated with morphine for 30 days. 35 Morphine also inhibited micturition in sickle mice similar to that observed clinically because of bladder retention caused by lowering of perfusion pressure and possibly by inducing renal pathology in these mice observed by us earlier. 9 36 37 Therefore, chronic morphine treatment leads to renal dysfunction in sickle mice.
To prevent the inadvertent effect of morphine on renal disease, we identified OPs and PDGFR-b, as targets of its mitogenic activity. Earlier, we identified KOP as one of the targets of morphine activity in the kidney using OP-specific knockout mice. 7 In the present study, we used pharmacological and genetic approaches to identify the receptors associated with the activity of morphine in the mesangial cells. Pharmacologically, both nor-BNI and MNTX inhibited morphine-induced signalling and proliferation, suggestive of the OP-mediated effect. The pKi of nor-BNI for KOP was shown to be 0.1 nM, and for MOP of 102 nM. 38 MNTX has a pKi of 8.0, 7.5, and 6.2 for MOP, KOP, and DOP, respectively. 39 Therefore, based on pharmacological inhibition, it is likely that morphine acts via MOP, KOP, or both agonism on mesangial cells. This is similar to our observations showing inhibition of morphine signalling after silencing of either MOP or KOP. It is therefore likely that morphine acts via more than one OP. Splice variants of MOP have been suggested to play a physiologically important role through heterodimerization. 40 Multiple bands of MOP observed by us are suggestive of the presence of splice variants and perhaps heterodimerization of MOP with KOP. Although not known in the kidney, OPs are known to act as heterodimers in some cell types 41 and therefore silencing or antagonizing one receptor may abrogate the activity of the other. An advantage of targeting KOP is that it may not antagonize morphine-analgesia, while MOP antagonists may block morphine-analgesia. It is possible that chronic treatment with morphine may lead to tolerance and therefore we administered escalating doses of morphine in our study. While activity of morphine via OPs may be reduced because of desensitization of OPs, it may act via non-opioid family of receptors. Indeed, morphine has been shown to bind to toll-like receptor 4 and promote neuroinflammation. 42 Therefore, targeting RTKs with Sunitinib-like clinically used drugs may prevent the inadvertent effect of morphine in the kidney. However, Sunitinib significantly inhibited mesangial cell proliferation, supporting the notion that RTKs are critical to the maintenance of normal mesangium. Therefore, doses of RTK inhibitors must be carefully determined or it may be safer to use OP antagonists, such as MNTX, to block morphine's mitogenic effect. The mechanistic understanding herein provides insights into ameliorating the inadvertent mitogenic activity of morphine in the kidney. As these studies are performed in mice, any alteration in clinical decision-making should not be made until proved in human studies.
